专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06486382B1 Use of the green fluorescent protein as a screenable marker for plant transformation 失效
标题翻译：使用绿色荧光蛋白作为植物转化的可筛选标记
公开(公告)号：US06486382B1
公开(公告)日：2002-11-26
申请号：US09214909
申请日：1999-12-20
申请人： William Gordan-Kamm , Dorothy A. Pierce , Benjamin Bowen , Dennis Bidney , Margit Ross , Christopher Scelonge , Michael D. Miller , Gary Sandahl , Lijuan Wang
发明人： William Gordan-Kamm , Dorothy A. Pierce , Benjamin Bowen , Dennis Bidney , Margit Ross , Christopher Scelonge , Michael D. Miller , Gary Sandahl , Lijuan Wang
IPC分类号： C12N1582
CPC分类号： C12N15/8216 , C07K14/43595 , C12N15/8209 , C12N15/8212 , C12N15/8213
摘要： A method for the production of transgenic plants is provided in which a vector carrying a gene encoding the green fluorescent protein is introduced into cells, the cells are screened for the protein and transformed cells are selected and regenerated. The cellular toxicity of the green fluorescent protein is circumvented by regulating expression of the gene encoding the protein or directing the protein to a subcellular compartment where it is not toxic to the cell. DNA constructs are provided for cell transformation in which the expression of a gene encoding the green fluorescent protein is placed under the control of an inducible promoter. In addition, DNA constructs are provided in which a nucleotide sequence encoding the green fluorescent protein is operably linked to a signal sequence which directs the expressed protein to a subcellular compartment where the protein is not toxic to the cell. Oxidative stress to plant cells transformed with GFP also can be ameliorated by transforming cells with an expression vector comprising genes encoding GFP and an oxygen scavenger enzyme such as superoxide dismutase. The toxicity of GFP in transformed plants can be eliminated by excising the screenable marker gene following detection of transformed cells or sectors. The FLP/FRT system is used in conjunction with GFP as a visible marker for transformation and FRT excision. A nucleotide sequence optimized for expression of the green fluorecent protein in plants is also provided.
摘要翻译：提供了一种用于生产转基因植物的方法，其中将携带编码绿色荧光蛋白的基因的载体导入细胞，筛选细胞以进行蛋白质，并选择和再生转化的细胞。绿色荧光蛋白的细胞毒性通过调节编码蛋白质的基因的表达或引导蛋白质转移到对细胞无毒性的亚细胞区域来避免。提供DNA构建体用于细胞转化，其中将编码绿色荧光蛋白的基因的表达置于诱导型启动子的控制之下。此外，提供了DNA构建体，其中编码绿色荧光蛋白的核苷酸序列可操作地连接到将表达的蛋白质导向亚细胞区域的信号序列，其中蛋白质对细胞无毒性。用GFP转化的植物细胞的氧化应激也可以通过用包含编码GFP和氧清除酶如超氧化物歧化酶的基因的表达载体转化细胞来改善。通过在检测到转化的细胞或部分后切除可筛选标记基因，可以消除GFP在转化植物中的毒性。 FLP / FRT系统与GFP结合使用，作为转化和FRT切除的可见标记。还提供了优化用于植物中绿色荧光蛋白表达的核苷酸序列。

2. 发明申请

US20120284029A1 PHOTO-REALISTIC SYNTHESIS OF IMAGE SEQUENCES WITH LIP MOVEMENTS SYNCHRONIZED WITH SPEECH 有权
标题翻译：具有与语音同步的LIP运动的图像序列的照片 - 现实综合
公开(公告)号：US20120284029A1
公开(公告)日：2012-11-08
申请号：US13098488
申请日：2011-05-02
申请人： Lijuan Wang , Frank Soong
发明人： Lijuan Wang , Frank Soong
IPC分类号： G10L21/00
CPC分类号： G10L21/10 , G10L2021/105
摘要： Audiovisual data of an individual reading a known script is obtained and stored in an audio library and an image library. The audiovisual data is processed to extract feature vectors used to train a statistical model. An input audio feature vector corresponding to desired speech with which a synthesized image sequence will be synchronized is provided. The statistical model is used to generate a trajectory of visual feature vectors that corresponds to the input audio feature vector. These visual feature vectors are used to identify a matching image sequence from the image library. The resulting sequence of images, concatenated from the image library, provides a photorealistic image sequence with lip movements synchronized with the desired speech.
摘要翻译：读取已知脚本的个人的视听数据被获取并存储在音频库和图像库中。处理视听数据以提取用于训练统计模型的特征向量。提供了与合成图像序列将被同步的期望语音相对应的输入音频特征向量。统计模型用于生成对应于输入音频特征向量的视觉特征向量的轨迹。这些视觉特征向量用于识别来自图像库的匹配图像序列。从图像库连接的所得到的图像序列提供了与期望语音同步的唇部运动的照片级逼真图像序列。

3. 发明申请

US20120116761A1 Minimum Converted Trajectory Error (MCTE) Audio-to-Video Engine 有权
标题翻译：最小转换轨迹误差（MCTE）音频到视频引擎
公开(公告)号：US20120116761A1
公开(公告)日：2012-05-10
申请号：US12939528
申请日：2010-11-04
申请人： Lijuan Wang , Frank Kao-Ping Soong
发明人： Lijuan Wang , Frank Kao-Ping Soong
IPC分类号： G10L15/00
CPC分类号： G10L21/06 , G10L21/10 , G10L2021/105
摘要： Embodiments of an audio-to-video engine are disclosed. In operation, the audio-to-video engine generates facial movement (e.g., a virtual talking head) based on an input speech. The audio-to-video engine receives the input speech and recognizes the input speech as a source feature vector. The audio-to-video engine then determines a Maximum A Posterior (MAP) mixture sequence based on the source feature vector. The MAP mixture sequence may be a function of a refined Gaussian Mixture Model (GMM). The audio-to-video engine may then use the MAP to estimate video feature parameters. The video feature parameters are then interpreted as facial movement. The facial movement may be stored as data to a storage module and/or it may be displayed as video to a display device.
摘要翻译：公开了音频到视频引擎的实施例。在操作中，音频到视频引擎基于输入语音产生面部动作（例如，虚拟通话头）。音频到视频引擎接收输入语音并将输入语音识别为源特征向量。音频到视频引擎然后基于源特征向量确定最大后验（MAP）混合序列。 MAP混合序列可以是精细高斯混合模型（GMM）的函数。音频到视频引擎然后可以使用MAP估计视频特征参数。视频功能参数被解释为面部动作。面部运动可以作为数据存储到存储模块和/或其可以作为视频显示到显示装置。

4. 发明申请

US20060229304A1 (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity 失效
公开(公告)号：US20060229304A1
公开(公告)日：2006-10-12
申请号：US11373770
申请日：2006-03-09
申请人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
发明人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
IPC分类号： A61K31/538 , C07D265/36 , A61K31/138
CPC分类号： C07D307/42 , A61K31/138 , A61K31/538 , C07B2200/07 , C07C217/84 , C07C217/86 , C07C217/88 , C07C217/90 , C07C239/20 , C07C323/19 , C07C323/20 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/65 , C07D251/42 , C07D333/20
摘要： The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

5. 发明申请

US20050148777A1 Benzopyran compounds useful for treating inflammatory conditions 失效
标题翻译：可用于治疗炎性疾病的苯并吡喃化合物
公开(公告)号：US20050148777A1
公开(公告)日：2005-07-07
申请号：US10801429
申请日：2004-03-16
申请人： Jeffery Carter , David Brown , Li Xing , Karl Aston , John Springer , Francis Koszyk , Steven Kramer , Renee Huff , Yi Yu , Bruce Hamper , Subo Laio , Angela Deprow , Theresa Fletcher , E. Hallinan , James Kiefer , David Limburg , Lijuan Wang , Cindy Ludwig , John McCall , John Talley
发明人： Jeffery Carter , David Brown , Li Xing , Karl Aston , John Springer , Francis Koszyk , Steven Kramer , Renee Huff , Yi Yu , Bruce Hamper , Subo Laio , Angela Deprow , Theresa Fletcher , E. Hallinan , James Kiefer , David Limburg , Lijuan Wang , Cindy Ludwig , John McCall , John Talley
IPC分类号： A61K31/352 , A61K31/382 , A61K31/395 , A61K31/47 , A61K31/4709 , A61P29/00 , C07D20060101 , C07D215/38 , C07D215/54 , C07D311/58 , C07D311/64 , C07D311/92 , C07D335/06 , C07D401/02 , C07D405/02 , C07D407/02 , C07D409/02 , C07D493/04
CPC分类号： C07D311/58 , C07D311/64 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06 , C07D493/04
摘要： The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R 2, R3, and R4 are as described in the specification.
摘要翻译：本发明涉及可用于治疗与环氧合酶-2介导的病症有关的病症的方法和化合物。特别感兴趣的化合物是苯并吡喃及其由式1定义的类似物，其中Z，X，R 1，R 2，R 3和R 4 >如说明书中所述。

6. 发明申请

US20050009838A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors 失效
标题翻译：哌啶基和哌嗪基 - 磺酰基甲基异羟肟酸及其作为蛋白酶抑制剂的用途
公开(公告)号：US20050009838A1
公开(公告)日：2005-01-13
申请号：US10618288
申请日：2003-04-25
申请人： Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , David Brown , Jeffery Carroll , Yiyuan Chen , Yvette Fobian , John Freskos , Alan Gasiecki , Margaret Grapperhaus , Robert Heintz , Susan Hockerman , Darren Kassab , Ish Khanna , Stephen Kolodziej , Mark Massa , Joseph McDonald , Brent Mischke , Deborah Mischke , Patrick Mullins , Mark Nagy , Monica Norton , Joseph Rico , Michelle Schmidt , Nathan Stehle , John Talley , William Vernier , Clara Villamil , Lijuan Wang , Thomas Wynn
发明人： Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , David Brown , Jeffery Carroll , Yiyuan Chen , Yvette Fobian , John Freskos , Alan Gasiecki , Margaret Grapperhaus , Robert Heintz , Susan Hockerman , Darren Kassab , Ish Khanna , Stephen Kolodziej , Mark Massa , Joseph McDonald , Brent Mischke , Deborah Mischke , Patrick Mullins , Mark Nagy , Monica Norton , Joseph Rico , Michelle Schmidt , Nathan Stehle , John Talley , William Vernier , Clara Villamil , Lijuan Wang , Thomas Wynn
IPC分类号： C07D295/22 , A61K31/451 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P1/02 , A61P1/04 , A61P1/14 , A61P1/16 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/08 , A61P13/02 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P25/00 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P37/02 , A61P39/00 , A61P41/00 , A61P43/00 , C07D211/66 , C07D211/96 , C07D213/74 , C07D309/08 , C07D335/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D411/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04 , A61K31/445 , C07D211/26
CPC分类号： C07D213/74 , C07D211/66 , C07D211/96 , C07D309/08 , C07D335/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D411/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04
摘要： This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
摘要翻译：本发明一般涉及蛋白酶（也称为“蛋白酶”）抑制剂，尤其涉及哌啶基和哌嗪基 - 磺酰基甲基异羟肟酸，其特别是抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP “）活性和/或蛋白聚糖蛋白聚糖酶活性。这种异羟肟酸通常在结构上对应于下式：（其中A 1，A 2，Y，E 1，E 2，E 3和R x如本说明书），并且还包括这些化合物的盐。本发明还涉及这种异羟肟酸的组合物，用于合成这种异羟肟酸的中间体，制备这种异羟肟酸的方法，以及用于治疗与MMP活性和/或蛋白聚糖蛋白聚糖酶活性相关的病症（特别是病理状态）的方法。

7. 发明授权

US06765023B2 Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity 失效
标题翻译：用于抑制胆固醇酯转移蛋白活性的取代的N，N-二取代的反向氨基醇化合物的用途
公开(公告)号：US06765023B2
公开(公告)日：2004-07-20
申请号：US10155921
申请日：2002-05-23
申请人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
发明人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
IPC分类号： A61K31133
CPC分类号： C07C323/25 , B01D2201/345 , C07B2200/07 , C07C215/08 , C07C215/16 , C07C217/58 , C07C217/84 , C07C217/88 , C07C217/90 , C07C217/92 , C07C219/06 , C07C219/28 , C07C219/34 , C07C225/22 , C07C229/38 , C07C229/52 , C07C229/60 , C07C233/25 , C07C233/43 , C07C233/69 , C07C233/80 , C07C235/20 , C07C235/24 , C07C235/56 , C07C237/30 , C07C237/38 , C07C255/13 , C07C255/21 , C07C255/24 , C07C255/54 , C07C255/58 , C07C271/28 , C07C275/34 , C07C275/40 , C07C311/21 , C07C311/58 , C07C317/32 , C07C317/36 , C07C323/19 , C07C323/20 , C07C323/31 , C07C323/32 , C07C323/37 , C07C323/44 , C07C323/65 , C07C327/30 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/18 , C07D207/335 , C07D209/82 , C07D213/38 , C07D213/62 , C07D225/08 , C07D239/26 , C07D239/34 , C07D251/46 , C07D257/04 , C07D263/04 , C07D265/14 , C07D295/088 , C07D295/108 , C07D295/135 , C07D295/192 , C07D307/04 , C07D307/38 , C07D333/20 , C07D333/28 , C07D491/10
摘要： The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted reverse aminoalcohols. A preferred specific N,N-disubstituted reverse aminoalcohols is the compound:
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-I）抑制剂的取代多环芳基和杂芳基叔杂烷基胺化合物以及用于治疗动脉粥样硬化和其它冠状动脉疾病的化合物，组合物和方法。优选的叔杂烷基胺化合物是取代的N，N-二取代的反向氨基醇。优选的具体的N，N-二取代的反向氨基醇是化合物：

8. 发明授权

US06683099B2 Substituted N,N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity 失效
标题翻译：可用于抑制胆固醇酯转移蛋白活性的取代的N，N-二取代的环烷基氨基醇化合物
公开(公告)号：US06683099B2
公开(公告)日：2004-01-27
申请号：US10155451
申请日：2002-05-23
申请人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
发明人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
IPC分类号： A61K31133
CPC分类号： C07C323/25 , B01D2201/345 , C07B2200/07 , C07C215/08 , C07C215/16 , C07C217/58 , C07C217/84 , C07C217/88 , C07C217/90 , C07C217/92 , C07C219/06 , C07C219/28 , C07C219/34 , C07C225/22 , C07C229/38 , C07C229/52 , C07C229/60 , C07C233/25 , C07C233/43 , C07C233/69 , C07C233/80 , C07C235/20 , C07C235/24 , C07C235/56 , C07C237/30 , C07C237/38 , C07C255/13 , C07C255/21 , C07C255/24 , C07C255/54 , C07C255/58 , C07C271/28 , C07C275/34 , C07C275/40 , C07C311/21 , C07C311/58 , C07C317/32 , C07C317/36 , C07C323/19 , C07C323/20 , C07C323/31 , C07C323/32 , C07C323/37 , C07C323/44 , C07C323/65 , C07C327/30 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/18 , C07D207/335 , C07D209/82 , C07D213/38 , C07D213/62 , C07D225/08 , C07D239/26 , C07D239/34 , C07D251/46 , C07D257/04 , C07D263/04 , C07D265/14 , C07D295/088 , C07D295/108 , C07D295/135 , C07D295/192 , C07D307/04 , C07D307/38 , C07D333/20 , C07D333/28 , C07D491/10
摘要： The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted cycloalkyl aminoalcohols. A preferred specific N,N-disubstituted cycloalkyl aminoalcohol is the compound:
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-I）抑制剂的取代多环芳基和杂芳基叔杂烷基胺化合物以及用于治疗动脉粥样硬化和其它冠状动脉疾病的化合物，组合物和方法。优选的叔杂烷基胺化合物是取代的N，N-二取代的环烷基氨基醇。优选的具体的N，N-二取代的环烷基氨基醇是化合物：

9. 发明授权

US06677380B2 Substituted N, N-disubstituted mercapto amino compounds useful for inhibiting cholesteryl ester transfer protein activity 失效
标题翻译：用于抑制胆固醇酯转移蛋白活性的取代的N，N-二取代的巯基氨基化合物
公开(公告)号：US06677380B2
公开(公告)日：2004-01-13
申请号：US10155346
申请日：2002-05-23
申请人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
发明人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
IPC分类号： A61K31145
CPC分类号： C07C323/25 , B01D2201/345 , C07B2200/07 , C07C215/08 , C07C215/16 , C07C217/58 , C07C217/84 , C07C217/88 , C07C217/90 , C07C217/92 , C07C219/06 , C07C219/28 , C07C219/34 , C07C225/22 , C07C229/38 , C07C229/52 , C07C229/60 , C07C233/25 , C07C233/43 , C07C233/69 , C07C233/80 , C07C235/20 , C07C235/24 , C07C235/56 , C07C237/30 , C07C237/38 , C07C255/13 , C07C255/21 , C07C255/24 , C07C255/54 , C07C255/58 , C07C271/28 , C07C275/34 , C07C275/40 , C07C311/21 , C07C311/58 , C07C317/32 , C07C317/36 , C07C323/19 , C07C323/20 , C07C323/31 , C07C323/32 , C07C323/37 , C07C323/44 , C07C323/65 , C07C327/30 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/18 , C07D207/335 , C07D209/82 , C07D213/38 , C07D213/62 , C07D225/08 , C07D239/26 , C07D239/34 , C07D251/46 , C07D257/04 , C07D263/04 , C07D265/14 , C07D295/088 , C07D295/108 , C07D295/135 , C07D295/192 , C07D307/04 , C07D307/38 , C07D333/20 , C07D333/28 , C07D491/10
摘要： The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted mercapto amines. A preferred specific N,N-disubstituted mercapto amine is the compound:
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-I）抑制剂的取代多环芳基和杂芳基叔杂烷基胺化合物以及用于治疗动脉粥样硬化和其它冠状动脉疾病的化合物，组合物和方法。优选的叔杂烷基胺化合物是取代的N，N-二取代的巯基胺。优选的具体的N，N-二取代巯基胺是化合物：

10. 发明授权

US06677379B2 Substituted N,N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity 失效
标题翻译：用于抑制胆固醇酯转移蛋白活性的取代的N，N-二取代的二氨基化合物
公开(公告)号：US06677379B2
公开(公告)日：2004-01-13
申请号：US10155095
申请日：2002-05-23
申请人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
发明人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
IPC分类号： A61K31133
CPC分类号： C07C323/25 , B01D2201/345 , C07B2200/07 , C07C215/08 , C07C215/16 , C07C217/58 , C07C217/84 , C07C217/88 , C07C217/90 , C07C217/92 , C07C219/06 , C07C219/28 , C07C219/34 , C07C225/22 , C07C229/38 , C07C229/52 , C07C229/60 , C07C233/25 , C07C233/43 , C07C233/69 , C07C233/80 , C07C235/20 , C07C235/24 , C07C235/56 , C07C237/30 , C07C237/38 , C07C255/13 , C07C255/21 , C07C255/24 , C07C255/54 , C07C255/58 , C07C271/28 , C07C275/34 , C07C275/40 , C07C311/21 , C07C311/58 , C07C317/32 , C07C317/36 , C07C323/19 , C07C323/20 , C07C323/31 , C07C323/32 , C07C323/37 , C07C323/44 , C07C323/65 , C07C327/30 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/18 , C07D207/335 , C07D209/82 , C07D213/38 , C07D213/62 , C07D225/08 , C07D239/26 , C07D239/34 , C07D251/46 , C07D257/04 , C07D263/04 , C07D265/14 , C07D295/088 , C07D295/108 , C07D295/135 , C07D295/192 , C07D307/04 , C07D307/38 , C07D333/20 , C07D333/28 , C07D491/10
摘要： The invention relates to substituted polycyclic aryl and heteroary tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound:
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-1）的抑制剂的取代多环芳基和杂芳基叔杂烷基胺化合物以及用于治疗动脉粥样硬化和其它冠状动脉疾病的化合物，组合物和方法。优选的叔杂烷基胺化合物是取代的N，N-二取代的二胺。优选的具体的N，N-二取代的二胺是化合物：

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式